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Bone is continually being remodeled and defects in the processes involved lead to bone
diseases. Many regulatory factors are known to inﬂuence remodeling but other mecha-
nisms, hitherto unknown, may also be involved. Importantly, our understanding of these
currently unknown mechanisms may lead to important new therapies for bone disease. It
is accepted that purinergic signaling is involved in bone, and our knowledge of this area
has increased signiﬁcantly over the last 15 years, although most of the published work
has studied the role of ATP and other signaling molecules via the P2 family of purinergic
receptors. During the last few years, however, there has been increased interest within the
bone ﬁeld in the role of P1 receptors where adenosine is the primary signaling molecule.
This review will bring together the current information available in relation to this expanding
area of research.
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PURINERGIC SIGNALING AND BONE
Bone is a dynamic living tissue that undergoes continuous and
life-long remodeling. This process is orchestrated by the three
bone cell types (osteoclasts, osteoblasts, and osteocytes) and is
modulated by many factors including mechanical forces and sol-
uble osteogenic and osteolytic compounds. Impairments in the
remodeling processes eventually lead to diseases such as osteo-
porosis. These bone diseases are major health problems and
especially affect speciﬁc groups of people, e.g., elderly individu-
als, patients treated with corticosteroids. Furthermore, arthritis
(e.g., rheumatoid arthritis, osteoarthritis) results in a heavy
toll on bone, particularly in relation to bone mineral density.
Although there is currently much insight into the systems that
maintain healthy bone, there is still a need to develop new
therapies.
It is well recognized that purines act as extracellular signal-
ing molecules by binding to and activating the P2 and P1 (or A)
family of purinergic receptors (Burnstock, 2011). These signal-
ing cascades are known to play key roles in both neuronal and
non-neuronal tissues, and there has, over the last 15 years, been
increasing interest in the speciﬁc functions of purinergic sig-
naling in the physiology and pathophysiology of bone. Much
of this reported work has investigated the speciﬁc role of ATP
and P2 receptors in bone homeostasis (Reyes et al., 2011; Gart-
land et al., 2012). Up until 6 years ago, however, very little was
known about the role of P1 (or A) receptors in bone. This review
will focus on recent developments in this research ﬁeld and will
include effects on mature osteoblasts and osteoclasts as well as
their respective precursor cells. We are not aware of any stud-
ies on the expression and function of adenosine receptors (ARs)
in osteocytes and these cells will not be included further in this
review.
ADENOSINE METABOLISM AND ADENOSINE RECEPTORS
Nucleotides such as ATP, ADP, GTP, and GDP occur in high con-
centrations (2–5 mM) within cells (Hoebertz et al., 2003; Evans
et al., 2006). The half-life of such molecules is, however, very
short and they are sequentially degraded to the corresponding
nucleoside by a family of phosphatases (e.g., ATP is sequentially
dephosphorylated to ADP), AMP and adenosine are then recycled
back to ATP by a series of speciﬁc kinases in a continuous cycle of
ATP breakdown and formation depending on the energy require-
ments of the cell (Collis and Hourani, 1993; Olah and Stiles, 1995;
Spychala, 2000; Fredholm et al., 2011; Figure 1). Under physio-
logical conditions adenosine concentrations inside of the cell are
relatively low (<1μM) and themajor regulatory enzyme is adeno-
sine kinase (AK) which mediates the initial phosphorylation step,
via AMP, back to ATP (Synder and Lukey, 1982; Pak et al., 1994;
Lloyd and Fredholm, 1995; Fredholm, 2010).
The recycling of adenosine and ATP is perturbed during con-
ditions of metabolic stress, high cellular activity or cell death,
and the increased phosphatase activity leads to excessive levels
of adenosine (Spychala, 2000). In addition there is increased facil-
itated diffusion and secondary active transport of nucleotides out
of the cell where the predominant enzyme activity is ecto-5′-
nucleotidase (CD73) leading to an accumulation of extracellular
adenosine (Figure 1) where it can activate the P1 (adenosine)
family of membrane bound receptors (Van Belle et al., 1987;
Latini et al., 1999; Lewis et al., 2006). In contrast to intracellu-
lar adenosine which is under the regulation of AK, extracellular
adenosine levels are critically regulated by adenosine deami-
nase (ADA) which degrades adenosine to inosine (Spychala,
2000). Another key enzyme that is important in the genera-
tion of ATP in the ATP–adenosine pathway is AMP-activated
protein kinase (AMPK). AMPK is a serine–threonine kinase that
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FIGURE 1 | Adenosine synthesis and metabolic pathways inside and
outside of a cell.Within the cell ATP and adenosine are continually recycled
depending on energy requirements via a series of dephosphorylation and
phosphorylation steps mediated by enzymes such as cytosolic
5′-nucleotidase (cyto-5′NT), adenosine kinase (AK), and AMP kinase (AMPK).
Under physiological conditions the rate limiting enzyme is AK. Adenosine
can also be generated from the hydrolysis of S-adenosyl-homocysteine
(SAH). In response to high metabolic activity ATP and adenosine is
extruded to the outside of the cell via facilitated diffusion and secondary
active transport. Under such conditions there is further degradation of
ATP to adenosine where it can activate adenosine receptors. Excess
adenosine is irreversibly deamidated to inosine by the enzyme
adenosine deaminase (ADA). Modiﬁed with permission from
Blackburn (2003).
regulates energy homeostasis and responds to diet and exercise
(Jeyabalan et al., 2012).
The Km (Michaelis constant denoting the substrate concen-
tration at which the reaction rate is at half-maximum) value
for ADA is much higher (70 μM) than that for AK (40 nM)
indicating that AK is activated at much lower concentrations
of adenosine compared to ADA (Spychala et al., 1996; Spychala,
2000). The relatively high Km value for ADA suggests it may
act as a switch for removing excessive extracellular adenosine.
Thus the ATP metabolic pathways within and outside of the cell
are quite different; ATP–adenosine interconversion is maintained
intracellularly by cytosolic 5′-nucleotidase and AK, and extracel-
lular ATP is converted to adenosine and inosine by CD73 and
ADA (Sala-Newby et al., 1999; Bianchi and Spychala, 2003; Hun-
sucker et al., 2005). The relative activities of CD73 and ADA
will also dictate whether a cell has a net adenosine-producing
phenotype; enzyme levels however can and do ﬂuctuate, e.g.,
raised adenosine levels in hypoxia appear to be due to increased
CD73 expression (Spychala, 2000; Eltzschig et al., 2003). Adeno-
sine can also be generated through the metabolism of the amino
acid, L-homocysteine via the enzyme, S-adenosyl-homocysteine
(SAH) hydrolase; this enzyme mediates the conjugation of
L-homocysteine and adenosine when the amino acid levels are
high and releases the components when L-homocysteine is low
and the demands for the amino acid are high (Lee et al., 2001).
In addition there is evidence to suggest that non-speciﬁc alkaline
phosphatases (ALPs) can also hydrolyseAMP to adenosine (Picher
et al., 2003).
ADENOSINE RECEPTORS
Activation of ARs is dependent on the presence of extracellular
adenosine which can bind to a family of four P1 or A receptors,
termed A1, A2A, A2B, and A3. All four receptors are G-protein
coupled, either Gs or Gi and signal primarily through the acti-
vation (A2A and A2B) or inhibition (A1 and A3) of cAMP
(Figure 2). The four receptors have also been reported to activate
phospholipase C and mitogen-activated protein kinase (Fred-
holm et al., 2001). There is strong homology between speciﬁc
ARs in different species and all are asparagine-linked glycopro-
teins with seven transmembrane sequences. The A1 receptor
comprises six exons (two of which are coding) and the other
ARs have two coding exons (Olah and Stiles, 2000; Fredholm
et al., 2001; Hasko et al., 2005). A1 and A2A receptors, in par-
ticular, can heterodimerize with D1 and D2 dopamine receptors
(Kudlacek et al., 2003; Fuxe et al., 2007; Kim and Palmiter, 2008)
and Group 1 and 2 metabotropic glutamate receptors (Di Lorio
et al., 1996; Ferre et al., 1999) providing another level of func-
tional control. There is also evidence to suggest that adenosine
can interact or activate ion channels such as L- and N-type cal-
cium channels (Mei et al., 1996), voltage-gated calcium channels
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FIGURE 2 | Adenosine receptor signaling. Adenosine mediates its action
via four G-protein coupled receptors, A1, A2A, A2B, and A3 that are
coupled primarily to the activation and inhibition of cAMP. There is also
evidence to suggest that accumulated cAMP is linked to the modulation
of ion-channel activity (reprinted from herbalzym.com).
(Chieng and Bekkers, 2001; McCool and Farroni, 2001) and K+
channels (Paisansathan et al., 2010). ARs are widely expressed,
and have different afﬁnities for adenosine – A1 and A2A recep-
tors are to a certain extent high afﬁnity receptors (Km < 30 nM)
whereas the A3 and particularly the A2B receptor are low afﬁn-
ity receptors (Km 1–20 μM). The A2B and A3 receptors are
thus only likely to be activated under high metabolic and stress-
ful cellular conditions (Spychala, 2000; Fredholm et al., 2001;
Pedata et al., 2007).
ADENOSINE METABOLISM AND BONE PHYSIOLOGY
It is plausible to suggest that enzymes involved in the ATP–
adenosine metabolic pathway could inﬂuence bone physiology.
A few years ago it was suggested that metformin, commonly used
for the treatment of type II diabetes and known to act via acti-
vation of AMPK, may have an effect on bone (Kanazawa et al.,
2008). In these studies the authors showed that metformin stim-
ulated type 1 collagen and osteocalcin expression, ALP enzyme
activity, and mineralization of MC3T3-E1 osteoblast cells. They
also suggested that AMPK was the mediating molecule as the
osteoblastogenic effects of metformin were reversed with spe-
ciﬁc AMPK inhibitors. Similar ﬁndings were found in studies
using primary rat calvarial osteoblasts and the rat ROS 17/2.8
osteoblast cell line (Shah et al., 2010) andmicro-computed tomog-
raphy (μ-CT) studies showed that AMPα1(−/−) knockout (KO)
mice had smaller cortical and trabecular compartments thanwild-
type mice (Shah et al., 2010). In addition to its stimulatory effects
on osteoblasts, AMPK also appears to mediate the inhibition
of bone resorption by down-regulating the receptor activator
of NF-κB ligand (RANKL) in osteoclasts (Lee et al., 2010; Jeya-
balan et al., 2012). Animals with germline deletions of AMPKβ1
and 2 also had reduced trabecular bone density and mass com-
pared with wild-type littermates, although there was no change in
osteoblast or osteoclast cell numbers (Quinn et al., 2010). These
results show that AMPK is important for maintaining homeo-
static bone density but has no effect on osteoclast function or
differentiation.
CD73, together with ADA are the primary enzymes involved
in the generation and metabolism of adenosine. St. Hilaire et al.
(2011) and Robson (2011) reported the existence of non-sense
or missense mutations in the CD73 gene (resulting in a non-
functional protein) in sibling members with lower extremity
arterial calciﬁcation in three families. The authors hypothesize that
reduced adenosine levels increases ALP activity and consequently
increased degradation of pyrophosphate to inorganic phosphate
which in turn affects arterial calciﬁcation. This would be of
signiﬁcance in the bone also as it is accepted that the bonemineral-
ization process depends on the regulated balance of many factors
including inducers such as inorganic phosphate and inhibitors
such as inorganic pyrophosphate (Mackenzie et al., 2012). More
recently, Takedachi et al. (2012) characterized the bone pheno-
type of cd73−/− mice, and investigated the involvement of CD73
and AR signaling in osteoblast differentiation in vitro. Analysis by
μ-CT showed that 13-week-old male cd73−/− mice had osteope-
nia, and that this was due to reduced trabecular bone volume,
decreased trabecular number and thickness, and increased trabec-
ular separation when compared to wild-type controls. Other work
measuring biochemical markers of bone formation showed that
osteocalcin (bone formation marker) was decreased in cd73−/−
mice whereas bone resorption markers [tartrate-resistant acid
phosphatase 5b (TRAP5b) and C-terminal telopeptide] were
comparable to wild-type animals. Quantitative RT-PCR further
substantiated the association of the osteoblast to the impaired
bone phenotype seen in these animals. These studies suggest that
the involvement of CD73 in bone homeostasis is directed to the
osteoblasts. Other work included in the paper describes a series of
ex vivo experiments using osteoblasts isolated from cd73−/− and
wild-type animals. The authors suggest that CD73 plays a role in
osteoblast differentiation but not in the development of osteoblast
progenitors. In addition, the authors describe experiments
with MC3T3 (a mouse osteoblast cell line) cells and conclude
that overall their work shows that CD73-generated adeno-
sine positively regulates osteoblast differentiation via A2B AR
signaling.
Skeletal abnormalities are also reported to be associated with
disorders of the immune system such as ADA deﬁciency which
may be related to increased osteoclast bone resorption through
activation of cytokine molecules (Hong, 1989). Studies in ADA
negative mice (ADA(−/−)) showed that they have reduced tra-
becular bone density and reduced RANKL but no change in
osteoprotegerin (OPG; Sauer et al., 2009). The reduced bone
turnover in ADA(−/−) animals appears to be due to decreased
osteoblastogenesis but little change in osteoclastogenesis. Inter-
estingly, the plasma RANKL/OPG ratio was also signiﬁcantly
increased inADA-deﬁcient patients (Sauer et al., 2009). These data
thus suggest that ADA is an important regulator of bone function
by altering primarily osteoblastogenesis.
ADENOSINE RECEPTORS AND BONE
The expression and function of ARs in bone cells were ﬁrst demon-
strated by Shimegi who showed that adenosine was mitogenic
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for the MC3T3-E1 osteoblast cell line (Shimegi, 1996, 1998). In
addition methotrexate, a drug frequently used to treat rheuma-
toid arthritis and thought to mediate its actions via the release
of adenosine (Chan and Cronstein, 2010), was shown to inhibit
ALP activity in MC3T3-E1 and rat bone marrow stromal cells
(Uehara et al., 2001). A seminal paper in 2006 showed that extra-
cellular adenosine was produced by human osteoprogenitor and
mesenchymal stem cells (MSCs; Evans et al., 2006). In addition,
this study demonstrated the presence of the four AR subtypes
(A1, A2A, A2B, A3) in these cell types and showed that adeno-
sine and other AR agonists modulate the secretion of (i) the
inﬂammatory cytokine IL-6 and (ii) OPG, a key modulator of
osteoclastogenesis.
Since this ﬁnding, a ﬂurry of key papers that support the
hypothesis that ARs play a key role in bone homeostasis have been
published. Thus we now have much more insight into the roles
of these receptors in osteoblasts and osteoclasts as well as in their
respective progenitor cells. To provide an overview of the literature
in relation to current understanding, the next sections will discuss
published work under separate headings for each of the AR sub-
types. These sections will include work undertaken in vitro on cell
lines and primary bone cells, as well as information gleaned from
working with AR KO mice. Mouse models that harbor a deletion
within each of the four ARs are now available for research pur-
poses (Yaar et al., 2005; Yang et al., 2006), and these have led to
signiﬁcant conclusions on different AR function in many tissues.
Signiﬁcantly, in the last few years most of these have also been
studied in relation to bone quality and density. Published studies
on the role of theA3AR in musculoskeletal tissues focus on arthri-
tis so this will be discussed in Section “Adenosine and Adenosine
Receptors in Arthritis.” We are not aware of any published stud-
ies that have explored bone density and quality in the A3 AR KO
mouse.
A1 ADENOSINE RECEPTOR
A1 ARs play important roles in promoting human monocyte
fusion into giant cells in vitro (Merrill et al., 1997), and in induc-
ing appropriate formation and function of osteoclasts (Kara et al.,
2010a). Surprisingly, however, when similar work was under-
taken using cells from A1 AR KO mice, although osteoclast
formation was defective in vitro, these animals exhibited normal
numbers of osteoclasts in vivo (Kara et al., 2010a,b). However,
these osteoclasts in vivo did not seem to be actively resorbing
bone. No morphological changes were observed in osteoblasts
in these animals and bone-labeling studies did not reveal a
change in bone-formation rates (Kara et al., 2010a). Consistent
with these ﬁndings, there was a signiﬁcant increase in bone
density in the A1 AR KO mice, and administration of an A1
AR antagonist prevented ovariectomy-induced bone loss (Kara
et al., 2010a). A recent paper by the same group (He and Cron-
stein, 2012) addressed the disparity between in vitro and in vivo
osteoclast formation described above and postulated that key
factors could be present in vivo but not in vitro. They thus
further delineate the mechanisms by which the A1 AR modu-
lates RANKL-induced signaling in osteoclastogenesis and con-
clude that the receptor regulates osteoclast formation by altering
tumor necrosis factor-receptor-associated factor/transformation
growth factor-β activated kinase-1 (TRAF/TAK1) signaling (He
and Cronstein, 2012). Pellegatti et al. (2011), however, show
very little expression of the A1 AR in quiescent or macrophage-
colony stimulating factor (M-CSF)/RANKL-stimulated human
monocytes and state that the A1 AR does not play a role
in osteoclastogenesis. They hypothesize that the differences
between their observations and those of others (Merrill et al.,
1997; Kara et al., 2010a,b) are due at least partially to species
difference.
Although it is known that A1 ARs are expressed in osteoblasts,
their roles are largely unknown. We (Gharibi et al., 2011a,b)
have recently shown that A1 AR expression and function in
MSCs and mouse 7F2 osteoblasts seemed to be more relevant
to adipocyte differentiation rather than osteoblast differentia-
tion. When MSCs and 7F2 cells were induced to differentiate to
adipocytes, the increased expression of adipocyte marker genes
such as CCAAT enhancer binding proteins β (C/EBPβ) and
lipoprotein lipase (LPL) was accompanied by signiﬁcant increases
in A1 AR expression. In support of these ﬁndings stable trans-
fection of the human A1 AR gene into 7F2 osteoblasts increased
the expression of LPL but decreased expression of ALP (Gharibi
et al., 2011b). Over expression of the A1 AR also enhanced lipid
accumulation as determined by oil red O and nile red labeling
(Gharibi et al., 2011b).
A2A ADENOSINE RECEPTOR
It has been reported that A2A ARs play an important role in
promoting human monocyte fusion into giant cells in vitro (Mer-
rill et al., 1997). The same group has very recently extended
their studies and shown that A2A AR ligation inhibits osteo-
clasts formation (Mediero et al., 2012a). This work demonstrated
that the A2A AR agonist, CGS 21680, inhibited osteoclast dif-
ferentiation and function, increased the percentage of immature
osteoclast precursors, and decreased IL-1β and tumor necro-
sis factor-α (TNF-α) secretion. Cathepsin K and osteopontin
mRNA expression increased in control and ZM241385 (A2A
AR antagonist) pretreated osteoclasts, and this was blocked
by CGS 21680. Furthermore, μ-CT analysis of A2A AR
KO mouse femurs showed a signiﬁcantly decreased bone vol-
ume/trabecular bone volume ratio, decreased trabecular number,
and increased trabecular space. These A2A AR KO mouse femurs
also showed an increased number of TRAP-positive osteoclasts,
with marked osteoclast membrane folding and increased bone
resorption.
It is well accepted that P2 purinergic receptors (especially the
P2X7 receptor) are involved in osteoclast formation and func-
tion. It has recently been shown (Pellegatti et al., 2011) that the
P2X7 receptor, ATP, adenosine, and ARs act in a concerted fash-
ion to promote fusion of M-CSF/RANKL-stimulated monocytes
into multinucleated osteoclasts. This work also showed that A2A
AR antagonism potently inhibited fusion, whilst CGS 21680, an
A2A agonist, potentiated fusion but was able to overcome P2X7
receptor blockade. Some of these observations are opposite to
those described by others (Mediero et al., 2012a) and a very recent
manuscript from the Cronstein group further disagrees with these
observations as it demonstrates a direct role of A2AARs in human
osteoclasts formation (Mediero et al., 2012b), i.e., results which tie
Frontiers in Endocrinology | Bone Research September 2012 | Volume 3 | Article 113 | 4
“fendo-03-00113” — 2012/9/15 — 13:53 — page 5 — #5
Ham and Evans Adenosine and bone
in with what they have previously shown in the mouse (Mediero
et al., 2012a).
A role for the A2A AR in bone homeostasis is further sup-
ported by observations indicating that in a collagen-induced
mouse model of arthritis signiﬁcantly less bone resorption was
observed in the CGS 21680-treated mice when compared to sham-
control and sham-CGS 21680 mice (Mazzon et al., 2011). These
observations are in agreement with other studies described above
using in vitro cell systems or A2A KO mice.
In relation to the osteoblast lineage, it has been shown that the
A2A AR plays a role in mouse bone marrow-derived MSC devel-
opment (Katebi et al., 2009). The authors conclude that adenosine
and the A2A AR play a critical role in promoting the proliferation
and differentiation of mouse bone marrow-derived MSCs. It has
also been shown using rat-derived MSCs, that the expression of
A2A AR was upregulated during later stages of osteoblastic dif-
ferentiation, when its activation stimulated ALP activity (Gharibi
et al., 2011a).
A2B ADENOSINE RECEPTOR
The A2B AR is expressed in human osteoclast precursors (qui-
escent monocytes) and in those activated with M-CSF/RANKL
(Pellegatti et al., 2011). Furthermore the same study did not
demonstrate an effect when an A2B AR antagonist was added to
an osteoclast formation assay. We are not aware of any further
information currently available relating to A2BAR expression and
function in osteoclast differentiation and activity.
There is, however, strong evidence for the involvement of the
A2B AR in osteoblast differentiation and function. It has been
shown that this receptor is functionally dominant in human osteo-
progenitor cells (Evans et al., 2006). It has also been shown that
the A2B AR was dominant in rat bone marrow-derived MSCs,
and its expression and activity were transiently upregulated at
early stages of osteoblastic differentiation. Both activation and
overexpression of A2B AR induced the expression of osteoblast-
related genes (runx2,ALP), as well as ALP activity, and stimulation
increased osteoblast mineralization (Gharibi et al., 2011a). Others
(Takedachi et al., 2012) have also concluded that the A2B AR is
important in osteoblast differentiation. Blockade of the A2B AR
with PSB603 prevented osteogenic differentiation when human
primary MSCs were stimulated to differentiate to osteoblasts in
the presence of the universal AR agonist (NECA; Costa et al.,
2011). This work also shows that A1, A2A, A2B, and A3 AR ago-
nists increased human primary osteoblasts proliferation, and that
this agonist-induced proliferation was prevented by a panel of
receptor antagonists speciﬁc for each of the four receptor sub-
types (Costa et al., 2011). This is in contrast to the work of others
(Evans et al., 2006) who report that NECA (AR universal agonist)
did not change cell numbers when using a human osteoprogenitor
cell line, even though the concentrations used were similar in both
studies.
Other work published this year (Carroll et al., 2012) focuses
on the differentiation of mouse MSCs to osteoblasts. The authors
build on what others have shown using in vitro pharmacological
approaches by investigating the role of the A2B AR in osteoblast
differentiation and function both ex vivo and in vivo using A2B
AR KO mice. Ex vivo studies showed that at 9 and 12 days after
osteo-induction, bone marrow from these KO mice showed fewer
mineralized nodules, demonstrating a reduction in osteoblast dif-
ferentiation. They also examined the expression of transcription
factors central to osteoblast differentiation, runx2 and osterix, and
found that with osteo-induction, the increase in the expression
of both runx2 and osterix was signiﬁcantly attenuated in the A2B
AR KO samples. Other studies involving activation of the A2B AR
or addition of a cAMP analog during differentiation led them to
conclude that the mechanism of effect involves, at least partially,
cAMP.
Carroll et al. (2012) also addresses the role of the A2B AR in
callus formation after fracture. μ-CT revealed that fracture cal-
luses of A2B AR KO mice showed a smaller overall total volume,
as well as a decrease in the ratio of bone volume to total callus
volume at 14 and 21 days post-fracture. Analysis of tissue sections
supported these ﬁndings. In addition, tissue from the fracture
callus in A2B AR KO mice tend to show decreased expression
of runx2 and osterix at 3 days post-fracture and showed signiﬁ-
cantly decreased expression at 7 days post-fracture, as compared
to wild-type animals. The authors conclude that such ﬁndings
suggest that the A2B AR is involved in aspects of the skeletal
repair process and its absence leads to delayed progression of
bone development during fracture repair in the A2B AR KO mice.
Furthermore, and unexpectedly, analysis of adult femurs showed
lower bone density in A2B AR KO mice as compared to wild-type
animals, and the A2B AR KO animals have signiﬁcantly shorter
femurs.
ADENOSINE AND ADENOSINE RECEPTORS IN ARTHRITIS
Adenosine is known to be released under tissue injury or cellular
stress and high concentrations (18–50μM)have been found in the
synovial ﬂuid of rheumatoid arthritis patients (Sottofattori et al.,
2001; Huang et al., 2004). The accumulation of adenosine in the
synovial ﬂuid could be due to inhibition of the AK enzyme; the
effects of such an inhibitor, ABT-702 (a selective non-nucleoside
AK inhibitor) have been investigated in the rat adjuvant arthritis
model (Boyle et al., 2001). Animals treated with ABT-702 showed
reduced cartilage and bone destruction, and an overall inhibi-
tion of paw volume and hence arthritis. These data would thus
suggest that adenosine plays a beneﬁcial role in bone formation.
One of the earliest reports that suggested a possible involvement of
adenosine in bonepathology in arthritis used the collagen-induced
arthritis model in mice, where administration of Z-5′-ﬂuoro-
4′,5′-didehydro-5′-deoxyadenosine (MDL 28,842 an irreversible
inhibitor of SAH hydrolase) had fewer bone lesions than control
animals (Wolos et al., 1993). Inhibitor treated animals also showed
a decrease in the incidence of arthritis as well as a delay in disease
development.
Further studies in murine MC3T3-E1 osteoblast cells showed
that adenosine can protect against cell death induced by hydro-
gen peroxide and these protective effects could be mediated
via A1 and A2A ARs (Fatokun et al., 2006). The actions of
adenosine on bone in the setting of rheumatoid arthritis could
be due to its anti-inﬂammatory properties; the A2A AR ago-
nist, CGS 21680, ameliorated arthritis in the collagen-induced
mouse by reducing bone resorption and inhibiting plasma
concentrations of IL-6, soluble IL-1 and TNF-α as well as nitric
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oxide synthase and cyclooxygenase-2 (Mazzon et al., 2011). In
recent years there has been a focus on the possible use of A3
AR agonists as therapeutic compounds in rheumatoid arthritis;
IB-MECA (A3 AR agonist) reduced pannus and ﬁbrosis for-
mation, cartilage and bone destruction, and the latter via a
decrease in the number of osteoclasts in the adjuvant mouse
model (Rath-Wolfson et al., 2006). In these experiments, IB-
MECA also appeared to down-regulate A3 AR expression and
several inﬂammatory related molecules (e.g., AKT, NFκB, TNF-α,
and RANKL).
Similar ﬁndings were found when the highly selective A3
AR agonist IB-MECA (CF101) was given orally to rats that
had been induced to develop osteoarthritis with monosodium
iodoacetate (Bar-Yehuda et al., 2009). The A3 receptor selective
antagonist MRS1220 reduced the beneﬁcial effects (inhibition
of bone destruction and down-regulation of NFκB and TNF-α)
of CF101. There is also evidence to show that the actions of
methotrexate, the mainstay drug for rheumatoid arthritis, are
mediated through activation of ARs. For example, in the case of
methotrexate-induced expression of the A3 receptor, addition of
CF101 with methotrexate enhances the effect of the AR antag-
onist (Ochaion et al., 2006). The non-speciﬁc AR antagonists,
theophylline and caffeine reversed the effect of methotrexate on
hindpaw swelling and ankylosis in experimental adjuvant arthritis
(Montesinos et al., 2000). Methotrexate also mediates its actions
via the transcription factor NURR1; such actions could also be
mimicked by adenosine and its stable analog, NECA, suggesting
that methotrexate may stimulate adenosine release (Ralph et al.,
2005). In vitro studies have also suggested that methotrexate, in
the context of rheumatoid arthritis, has an inhibitory action on
osteoclastogenesis which is abolished by adenosine acting through
the A2B AR. Furthermore adenosine injected into the ankle joints
of methotrexate-treated adjuvant arthritic animals suppressed
the effect of methotrexate on bone destruction (Teramachi et al.,
2011). These data may suggest that adenosine has a stimulatory
effect on osteoclastogenesis.
ARs AS THERAPEUTIC TARGETS
Adenosine receptors have long been considered to be possible
therapeutic targets in a wide range of conditions including car-
diac, pulmonary, immunological, and inﬂammatory disorders
(Fredholm,2003,2010; Jacobson andGao,2006). Medicinal chem-
istry approaches have led to the development of selective and
potent agonists and antagonists for each of the four AR sub-
types (Muller and Jacobson, 2011), and many such compounds
have been, or are currently, in clinical trials. For example, IB-
MECA (CF101, developed by Can-Fite BioPharma), an A3 AR
agonist, was recently demonstrated to be efﬁcacious in clini-
cal trials of rheumatoid arthritis, psoriasis and dry eye disease
(http://www.canﬁte.com) and further clinical trials are planned
for osteoarthritis and glaucoma (Muller and Jacobson, 2011).
Inhibitors of nucleoside metabolism also represent an alter-
native therapeutic strategy that has gained increasing attention
in recent years (Boison, 2011). The augmentation of nucleoside
function by inhibiting their metabolism has several advantages
including the potential of affecting several signal transduction
pathways simultaneously and may thus be suitable for ﬁne-tuning,
restoring, or amplifying the physiological functions of adeno-
sine. Of special interest also is the development of radioligands
for in vivo imaging of ARs for diagnostic use in the CNS and in
the periphery. Ligands for in vivo positron emission tomographic
(PET) imaging of A1, A2A, and A3 ARs have been developed to
date and it will be interesting to see whether they will play a role
in furthering our knowledge of ARs in musculoskeletal tissues.
Generally speaking, however, we need to accumulate more data
of the mode of action of ARs in human bone before any of the
AR agonists and antagonists currently available are used in bone
disease related clinical trials.
CONCLUSION
It is clear from thework reported here that there is currently strong
evidence to support a role for adenosine and its receptors in bone
homeostasis, and these signaling pathways could have signiﬁcant
relevance in bone diseases such as osteoporosis and arthritis. There
have been major advances in the ﬁeld in recent years, but there
is much more to learn. Most of the studies to date utilize cells
(cell lines and primary) in vitro, or animal models ex vivo and in
vivo. Studies using human material are thus required urgently to
complement what is already known. As our knowledge of adeno-
sine metabolism and signaling pathways accumulates, we will also
hopefully move toward developing new therapeutic strategies for
bone disease.
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